Document Detail


Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura.
MedLine Citation:
PMID:  9169254     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
High-dose intravenous immunogammaglobulin (h.d.IgG) has been proposed as a treatment of idiopathic thrombocytopenic purpura (ITP), but the clinical effect is usually short and adverse reactions have been reported in clinical studies using different immunoglobulin (Ig) preparations. In this study, the efficacy of a last-generation polyvalent immunoglobulin in the treatment of ITP in adults and the incidences of adverse reactions of this therapy were evaluated. The reported data were based on various clinical and laboratory parameters evaluated before, during and after therapy, with a follow-up of 6 months. The data showed administration of 400 mg/kg d of intravenous polyvalent intact IgG for 5 days significantly increased the platelet count in all 15 patients, the maximum level occurring on Day 10 and being maintained in some patients for 6 months. Its very rapid onset of action suggests it may be useful for correcting life-threatening thrombocytopenia where bleeding complicates the clinical course, and for severe ITP in seriously immunosuppressed or infected patients in whom corticosteroids or immunosuppressive agents cannot be safely administered. The treatment was also well tolerated. In conclusion, polyvalent Ig may be useful in ITP steroid-refractory patients; further studies are required to evaluate clinical-laboratory parameters related to the long-term response of patients.
Authors:
P Pacetti; D Garau; C Caramatti; L Mangoni; V Zamboni; N Canova; V Rizzoli
Related Documents :
19170164 - Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenit...
24589454 - A randomized, controlled, multicenter contraceptive efficacy clinical trial of the intr...
24993354 - Improvement in the repair of defects in maxillofacial soft tissue in irradiated minipig...
18161784 - Danazol therapy for aplastic anemia refractory to immunosuppressive therapy.
20074264 - Short-term recovery after subtotal and total abdominal hysterectomy--a randomised clini...
21204044 - Percutaneous management of peripheral vascular malformations: a single center experience.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Current medical research and opinion     Volume:  13     ISSN:  0300-7995     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  1997  
Date Detail:
Created Date:  1997-08-05     Completed Date:  1997-08-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  517-27     Citation Subset:  IM    
Affiliation:
Department of Haematology, University of Parma, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Cell Count
Female
Follow-Up Studies
Humans
Immunoglobulin G / blood
Immunoglobulins, Intravenous / administration & dosage,  adverse effects,  therapeutic use*
Male
Megakaryocytes
Middle Aged
Platelet Count
Purpura, Thrombocytopenic, Idiopathic / therapy*
Chemical
Reg. No./Substance:
0/Immunoglobulin G; 0/Immunoglobulins, Intravenous

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical evaluation of indomethacin-containing patches for osteoarthritis and extremity trauma.
Next Document:  Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itchi...